|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:686-692
© 2006 The American Association for Thoracic Surgery
Evolving Technology |
a Cleveland Clinic Foundation, Cleveland, Ohio
b VCURES/Virginia Commonwealth University Medical Center, Richmond, Va
c Deutsches Herzzentrum, Berlin, Germany
d Gaston Memorial Hospital, Gastonia, NC
e Houston North West Medical Center, Houston, Tex
f Duke University Medical Center, Durham, NC
Received for publication July 7, 2005; revisions received October 10, 2005; accepted for publication October 20, 2005. * Address for reprints: Nicholas G. Smedira, MD, Cleveland Clinic Foundation, 9500 Euclid Ave/Desk F24, Cleveland, OH 44195. (Email: smedirn{at}ccf.org).
OBJECTIVES: Unfractionated heparin has many shortcomings, including indirect and partial inhibition of thrombin, antibody formation, and platelet activation. Bivalirudin, a short-acting direct thrombin inhibitor, avoids these limitations and has superior outcomes during percutaneous revascularization. This trial was performed to evaluate the safety and efficacy of bivalirudin in off-pump coronary artery bypass grafting.
METHODS: An open-label, multicenter randomized trial compared heparin with protamine reversal to bivalirudin in patients undergoing off-pump coronary artery bypass. The primary objective was safety as demonstrated by similar rates of procedural success defined as freedom from a composite of death, myocardial infarction, stroke, and repeat revascularization. Twenty-one institutions randomized 105 patients to receive bivalirudin and 52 patients to receive heparin.
RESULTS: The mean age was 65 years for both groups. The bivalirudin group had more grafts: 3.0 ± 1 versus 2.5 ± 1. Procedural success rates at 30 days were identical in bivalirudin- and heparin-treated patients (93%). Operative times, total blood loss, reoperations for bleeding, and major adverse events were not significantly different. Strokes were more frequent in the heparin group: 5.5% versus 0; P = .05. Mortality was 2% in each group. Repeat revascularization was required in 3% of bivalirudin- and 2% of the heparin-treated patients.
CONCLUSIONS: For patients undergoing off-pump coronary artery bypass grafting, bivalirudin was an effective anticoagulant, without excessive bleeding and with a safety profile similar to that of heparin. Further trials are warranted to assess whether anticoagulation with bivalirudin improves clinical outcomes.
Related Articles
J. Thorac. Cardiovasc. Surg. 2006 131: 515-516.
J. Thorac. Cardiovasc. Surg. 2006 131: 533-539.
This article has been cited by other articles:
![]() |
A Koster, S Buz, T Krabatsch, R Yeter, and R Hetzer Bivalirudin anticoagulation during cardiac surgery: a single-center experience in 141 patients Perfusion, January 1, 2009; 24(1): 7 - 11. [Abstract] [PDF] |
||||
![]() |
B. Kiaii, R. S. McClure, P. Stewart, R. Rayman, S. A. Swinamer, Y. Suematsu, S. Fox, J. Higgins, C. Albion, W. J. Kostuk, et al. Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up J. Thorac. Cardiovasc. Surg., September 1, 2008; 136(3): 702 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. A Czosnowski, S. W Finks, and K. C Rogers Bivalirudin for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery Ann. Pharmacother., September 1, 2008; 42(9): 1304 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF] |
||||
![]() |
C. M. Dyke, G. Aldea, A. Koster, N. Smedira, E. Avery, S. Aronson, B. D. Spiess, and A. M. Lincoff Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies Ann. Thorac. Surg., September 1, 2007; 84(3): 836 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Schroder, M. A. Daneshmand, N. R. Villamizar, R. P. Petersen, L. J. Blue, I. J. Welsby, A. J. Lodge, T. L. Ortel, J. G. Rogers, and C. A. Milano Heparin-Induced Thrombocytopenia in Left Ventricular Assist Device Bridge-to-Transplant Patients Ann. Thorac. Surg., September 1, 2007; 84(3): 841 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Koster, Y. Weng, W. Bottcher, T. Gromann, H. Kuppe, and R. Hetzer Successful Use of Bivalirudin as Anticoagulant for ECMO in a Patient With Acute HIT Ann. Thorac. Surg., May 1, 2007; 83(5): 1865 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pappalardo, A. Franco, G. Crescenzi G, A. Poli, A. Zangrillo, and A. Koster Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy Perfusion, January 1, 2007; 22(1): 67 - 69. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |